January 19, 2024
Kenvue investors who bought into the multibillion-dollar pharmaceutical company's May 2023 initial public offering have named its executives and former parent company Johnson & Johnson in a proposed class action concerning their alleged failure to disclose the low efficacy of phenylephrine, an ingredient in cash cow nasal decongestants including Tylenol and Benadryl products.